Dizal (jiangsu) Pharmaceutical Co. Ltd. Class ASSE: 688192

Announcement on Inclusion of Global Registered Clinical Study on Zegfrovy in the Oral Presentation at the 2025 World Conference on Lung Cancer (WCLC) and the Selection of Multiple Studies In the Field of Non-Small Cell Lung Cancer

· Issued by Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A via Shanghai Stock Exchange
Announcement on Inclusion of Global Registered Clinical Study on Zegfrovy in the Oral Presentation at the 2025 World Conference on Lung Cancer (WCLC) and the Selection of Multiple Studies In the Field of Non-Small Cell Lung Cancer

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis